An Open-Label Safety Study to Assess the Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Topical Treatment With Halobetasol Propionate 0.05% Topical Spray (Sun Pharmaceuticals Industries Limited) in Patients With Moderate to Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2018
At a glance
- Drugs Ulobetasol (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Sun Pharmaceutical Industries
- 02 Nov 2018 Status changed from suspended to discontinued.
- 31 Aug 2018 Biomarkers information updated
- 15 Feb 2018 Status changed from active, no longer recruiting to suspended.